// App-Quantinova.ai

TPS9597 : A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.

Researchers

Presenter

  • Emma Jane Dean

Principal Investigators

  • Romina Girotti

  • Ion Niculescu-Duvaz

  • Filipa Lopes

  • Lawrence Davies

  • Dan Niculescu-Duvaz

  • Natalie Dhomen

  • Sally Ellis

  • Zohra Ali

  • Brent O'Carrigan

  • Louise Carter

  • Luke Chisolm

  • Caroline Dive

  • Heidi A Lane

  • Paul Lorigan

  • Martin Eric Gore

  • James Larkin

  • Richard Marais

  • Caroline Springer

Medical Centers

  • University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Cancer Research UK Manchester Institute, Manchester, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Basilea Pharmaceutica International Ltd, Basel, Switzerland

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

Locations

  • United Kingdom

  • Switzerland

Companies

  • Basilea Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT02437227

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved